Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-CXCL11 antibody [EPR21755-173] (ab216157)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR21755-173] to CXCL11
  • Suitable for: WB, IP
  • Reacts with: Human

Overview

  • Product name

    Anti-CXCL11 antibody [EPR21755-173]
    See all CXCL11 primary antibodies

  • Description

    Rabbit monoclonal [EPR21755-173] to CXCL11

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    IP
    Human
    WB
    Human
    See all applications and species data

  • Immunogen

    Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • WB: Human CXCL11 recombinant protein (aa22-94); THP-1 treated with 200 ng/ml interferon-gamma (ab9659) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, followed by 300 ng/ml Brefeldin A (BFA) for 20 hours, whole cell lysate. IP: THP-1 treated with 200 ng/ml interferon-gamma (ab9659) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, followed by 300 ng/ml Brefeldin A (BFA) for 20 hours, whole cell lysate.

  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.

    One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.

    Learn more here.

Properties

Images

  • Western blot - Anti-CXCL11 antibody [EPR21755-173] (ab216157)
    Western blot - Anti-CXCL11 antibody [EPR21755-173] (ab216157)
    Anti-CXCL11 antibody [EPR21755-173] (ab216157) at 1/1000 dilution + Human CXCL11 recombinant protein (aa 22-94) at 0.01 µg

    Secondary
    Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Developed using the ECL technique.

    Predicted band size: 10 kDa
    Observed band size: 9 kDa
    why is the actual band size different from the predicted?


    Exposure time: 15 seconds


    Blocking/Dilution: 5% NFDM/TBST

     

  • Western blot - Anti-CXCL11 antibody [EPR21755-173] (ab216157)
    Western blot - Anti-CXCL11 antibody [EPR21755-173] (ab216157)
    All lanes : Anti-CXCL11 antibody [EPR21755-173] (ab216157) at 1/1000 dilution

    Lane 1 : THP-1 (hman monocytic leukemia cell line) whole cell lysate
    Lane 2 : THP-1 treated with 200 ng/ml interferon-gamma (IFN-gamma, ab9659) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, then 300 ng/ml Brefeldin A (BFA) was added to the treated cells for 20 hours, whole cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

    Developed using the ECL technique.

    Predicted band size: 10 kDa
    Observed band size: 11 kDa why is the actual band size different from the predicted?


    Exposure time: 37 seconds


    Blocking/Dilution: 5% NFDM/TBST

    The expression profile observed is consistent with what has been described in the literature (PMID: 17142784).

  • Immunoprecipitation - Anti-CXCL11 antibody [EPR21755-173] (ab216157)
    Immunoprecipitation - Anti-CXCL11 antibody [EPR21755-173] (ab216157)

    CXCL11 was immunoprecipitated from 0.35mg of THP-1 (human monocytic leukemia cell line) whole cell lysate with ab216157 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab216157 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/5,000 dilution.

    Lane 1: THP-1 (human monocytic leukemia cell line) treated with 200 ng/ml interferon-gamma (IFN-gamma, ab9659) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, then added 300 ng/ml Brefeldin A (BFA) for 20 hours, whole cell lysate 10ug (Input).
    Lane 2: ab216157 IP in THP-1 treated with 200 ng/ml interferon-gamma (IFN-gamma, ab9659) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, then added 300 ng/ml Brefeldin A (BFA) for 20 hours, whole cell lysate. 
    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab216157 in THP-1 treated with 200 ng/ml interferon-gamma (IFN-gamma, ab9659) and 50 ng/ml lipopolysaccharide (LPS) for 24 hours, then added 300 ng/ml Brefeldin A (BFA) for 20 hours, whole cell lysate.

    Blocking/Dilution buffer: 5% NFDM/TBST

  • Anti-CXCL11 antibody [EPR21755-173] (ab216157)
    Anti-CXCL11 antibody [EPR21755-173] (ab216157)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-CXCL11 antibody [EPR21755-173] (ab216157)

© 2021 Astana Biomed Group LLP. All rights reserved.